/
APGE
$132.71+$0.16 (+0.12%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$10.0B
75M shares
52-week range
$34.34 – $133.16
100% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.26%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$111.48
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $1.4M |
| Gross profit | $0 | $0 | $0 | −$1.4M |
| Gross margin | — | — | — | — |
| R&D | $27.8M | $68.4M | $167.9M | $214.7M |
| Operating income | −$30.7M | −$93.0M | −$216.9M | −$285.6M |
| EBITDA | −$39.8M | −$75.0M | −$181.9M | −$254.1M |
| Net income | −$39.8M | −$84.0M | −$182.1M | −$255.8M |
| Net margin | — | — | — | — |
| EPS (diluted) | -0.79 | -1.66 | -3.30 | -4.22 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $9M | $-4.44 | $-4.78–$-4.24 | 10 |
| 2027 | $12M | $-5.54 | $-6.30–$-4.94 | 10 |
| 2028 | $54M | $-6.08 | $-12.69–$-2.72 | 11 |
| 2029 | $239M | $-5.57 | $-5.57–$-5.57 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.09
Price
$132.71
Implied downside
-98%
Peer comparison
Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
www.apogeetherapeutics.com- Employees
- 261
- IPO / List date
- Jul 14, 2023
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds APGE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 41,100 | $1.8M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2008-01-08 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded APGE yet.
